Pharma BD Deal Intelligence

Amgen Inc. / BeiGene Ltd.

2020 · Licensing/Option · $2.8B · Complete

Announcement Sentiment

Strongly positive

Outcome Score

Largely worked — most objectives met.

Amgen entered a strategic collaboration with BeiGene to expand its oncology presence in China, investing $2.7B for a 20.5% equity stake with BeiGene commercializing 20 Amgen oncology products in China.

Key facts

Announced Jan 02, 2020
Closed Jan 02, 2020
Deal value $2.8B
Deal type Licensing/Option
Therapeutic area Oncology
Indications Multiple cancers
Key assets Xgeva, Kyprolis, Blincyto, AMG 510 (sotorasib)
Mechanism Multiple

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals